Differential Expression of RAGE,EGFR and Ki-67 in Primary Tumors and Lymph Node Deposits of Breast Carcinoma |
| |
| Authors: | Tarek Aboushousha1Olfat Hammam1Gehan Safwat2Ahmed Eesa3Shaza Ahmed2Mohamed Emad Esmat4Ahmed Hazem Helmy4 |
| |
| Affiliation: | 1Department of Pathology, Theodor Bilharz Research Institute, Cairo, Egypt.2Faculty of Biotechnology, October university for Modern Sciences and Arts, Cairo, Egypt.3Department of Pathology, Faculty of Medicine, Cairo university, Cairo, Egypt.4Department of Surgery, Faculty of Medicine, Cairo university, Cairo, Egypt. |
| |
| Abstract: | Background: Breast cancer is a complex disease that results from the inheritance of a number of susceptible genes.Intensive search wok was conducted world-wide on molecular bases of breast cancer in order to achieve the besttherapeutic modalities; however, breast cancer still remains a challengeable task. It is very important to determine ifthe biological parameters in metastatic regional lymph nodes are similar to that in the primary breast cancer becausetherapy is indicated for patients with synchronous metastatic regional lymph nodes of breast cancer. Difference intherapeutic response in cases of breast cancer may be assumed partially to variability in the biological behavior of tumortissue in primary breast cancer and lymph node metastasis. Aim: Our aim is to evaluate any variability in the expression ofthree types of tissue markers in both the primary breast tumors and corresponding axillary lymph nodes in order toexpect the targeted therapeutic effect on both sites. Material and Methods: Three markers from different categories;RAGE, EGFR and Ki-67 were immunohistochemicalyl studied for their expression in biopsy specimens from primarybreast tumors and their corresponding axillary lymph nodes. Results: There was a statistically significant difference inthe expression of these markers between benign and malignant breast lesions.Although we found some differences inthe expression of the three studied markers between primary breast cancer and corresponding axillary lymph nodes, yetthese variations were mostly not statistically significant. Conclusion: Our findings support the validity of anti-RAGEand anti-EGFR therapy for treatment of both primary and nodal metastatic breast cancer in immunopositive cases. |
| |
| Keywords: | IHC RAGE EGFR Ki-67 breast cancer |
|
| 点击此处可从《Asian Pacific journal of cancer prevention》浏览原始摘要信息 |
|
点击此处可从《Asian Pacific journal of cancer prevention》下载免费的PDF全文 |
|
